TY - JOUR
T1 - Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
AU - Watanabe, Mitsuhiro
AU - Houten, Sander M.
AU - Wang, Li
AU - Moschetta, Antonio
AU - Mangelsdorf, David J.
AU - Heyman, Richard A.
AU - Moore, David D.
AU - Auwerx, Johan
PY - 2004/5
Y1 - 2004/5
N2 - We explored the effects of bile acids on triglyceride (TG) homeostasis using a combination of molecular, cellular, and animal models. Cholic acid (CA) prevents hepatic TG accumulation, VLDL secretion, and elevated serum TG in mouse models of hypertriglyceridemia. At the molecular level, CA decreases hepatic expression of SREBP-1c and its lipogenic target genes. Through the use of mouse mutants for the short heterodimer partner (SHP) and liver X receptor (LXR) α and β, we demonstrate the critical dependence of the reduction of SREBP-1c expression by either natural or synthetic farnesoid X receptor (FXR) agonists on both SHP and LXRα and LXRβ. These results suggest that strategies aimed at increasing FXR activity and the repressive effects of SHP should be explored to correct hypertriglyceridemia.
AB - We explored the effects of bile acids on triglyceride (TG) homeostasis using a combination of molecular, cellular, and animal models. Cholic acid (CA) prevents hepatic TG accumulation, VLDL secretion, and elevated serum TG in mouse models of hypertriglyceridemia. At the molecular level, CA decreases hepatic expression of SREBP-1c and its lipogenic target genes. Through the use of mouse mutants for the short heterodimer partner (SHP) and liver X receptor (LXR) α and β, we demonstrate the critical dependence of the reduction of SREBP-1c expression by either natural or synthetic farnesoid X receptor (FXR) agonists on both SHP and LXRα and LXRβ. These results suggest that strategies aimed at increasing FXR activity and the repressive effects of SHP should be explored to correct hypertriglyceridemia.
UR - http://www.scopus.com/inward/record.url?scp=85047694456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047694456&partnerID=8YFLogxK
U2 - 10.1172/JCI21025
DO - 10.1172/JCI21025
M3 - Article
C2 - 15146238
AN - SCOPUS:85047694456
SN - 0021-9738
VL - 113
SP - 1408
EP - 1418
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 10
ER -